Skip to main content

Penumbra Inc

corporate_fare Company Profile

Penumbra Inc

PEN·NYSE·Life Sciences·CIK 0001321732

Penumbra, Inc. develops, manufactures, and markets medical technologies for challenging conditions like ischemic stroke, venous thromboembolism (including pulmonary embolism), and acute limb ischemia. The company specializes in thrombectomy, focusing on removing blood clots from the body using computer assisted vacuum thrombectomy (CAVT). Penumbra's product portfolio also includes technologies for embolization and access. Founded in 2004, Penumbra has introduced products into the thrombectomy market since 2007, the access market since 2008, the embolization market since 2011, and the neurosurgical market since 2014. The company's research and development activities support regulatory submissions and demonstrate product effectiveness. Penumbra aims to provide cost-effective products to specialist physicians and other healthcare providers to improve clinical and health outcomes. When a new generation product is introduced, sales of the older product typically decline.

Penumbra Inc (NYSE:PEN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 26 items for PEN at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Penumbra to be Acquired by Boston Scientific for $15 Billion, Offering Significant Premium
  • Penumbra Inc. Agrees to Be Acquired by Boston Scientific for $374.00 Cash and Stock per Share
  • Penumbra to be acquired by Boston Scientific for $374 per share in cash and stock
  • Penumbra to be Acquired by Boston Scientific for $14.5 Billion, Offering Significant Premium
  • Penumbra to be Acquired by Boston Scientific for $14.5 Billion in Cash and Stock

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$1.4B
Net Income
$177.69M
Diluted EPS
$4.52
Op. Cash Flow
$238.66M
Free Cash Flow
$174.93M
Gross Profit
$942.44M
Operating Income
$189.25M
Cash & Equivalents
$186.9M
Debt / Equity
0.00×
Net Margin
12.7%
Shares Outstanding
39.23M sh
Source: 10-K · filed 2026-02-25 · accession 0001321732-26-000007
$319.12
52-week range · as of 2026-07-30 $221.26 – $362.41
Market cap
$12.58B
Volume
205.4K (0.6× avg)
3-mo avg 351.2K
Live data · 2026-11-22 12:45 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed PEN - Filings & News (Page 2)

PEN
Jan 15, 2026, 5:20 PM EST
Filing Type: 425
Importance Score:
10
Price at Filing: $354.66
Real-time Price: $319.12 info
Change: -$35.54 (-10%) info
Market Cap: $12.578B info
PEN
Jan 15, 2026, 5:07 PM EST
Filing Type: 425
Importance Score:
10
Price at Filing: $354.66
Real-time Price: $319.12 info
Change: -$35.54 (-10%) info
Market Cap: $12.578B info
PEN
Jan 15, 2026, 4:44 PM EST
Filing Type: 425
Importance Score:
10
Price at Filing: $350.97
Real-time Price: $319.12 info
Change: -$31.85 (-9%) info
Market Cap: $12.578B info
PEN
Jan 15, 2026, 7:49 AM EST
Filing Type: 425
Importance Score:
10
Price at Filing: $355.74
Real-time Price: $319.12 info
Change: -$36.62 (-10%) info
Market Cap: $12.578B info
PEN
Jan 15, 2026, 7:26 AM EST
Filing Type: 425
Importance Score:
10
Price at Filing: $355.00
Real-time Price: $319.12 info
Change: -$35.88 (-10%) info
Market Cap: $12.578B info
PEN
Jan 15, 2026, 7:15 AM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $351.00
Real-time Price: $319.12 info
Change: -$31.88 (-9%) info
Market Cap: $12.578B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets